Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company's Vision to Transform Patient Outcomes in Rare DiseasesGlobeNewsWire • 01/09/23
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial OfficerGlobeNewsWire • 01/03/23
Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023GlobeNewsWire • 12/21/22
Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and ExpositionGlobeNewsWire • 12/12/22
Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent α- and β-Thalassemia at 64th ASH Annual MeetGlobeNewsWire • 12/10/22
PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult PatientsGlobeNewsWire • 11/10/22
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/03/22
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® RoyaltyGlobeNewsWire • 10/27/22
Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022GlobeNewsWire • 10/20/22
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial OfficerGlobeNewsWire • 09/26/22
Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult PatientsGlobeNewsWire • 09/16/22
Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase DeficiencyGlobeNewsWire • 08/18/22
Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-ThalassemiaGlobeNewsWire • 08/11/22
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive OfficerGlobeNewsWire • 08/08/22
Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/07/22